At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Controlled Study of Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
In Brief
A Phase 4 clinical trial evaluating Amikacin and Normal saline for Non-Cystic Fibrosis Bronchiectasis. Completed, enrolled 178 participants across 1 site.
Detailed Summary
This is a multi-centered, randomized, controlled study to assess the efficacy, indications and adverse reactions of combined administration of nebulized amikacin in patients with acute exacerbation of non-cystic fibrosis bronchiectasis and to evaluate whether inhaled antibiotics are more likely to cause bacterial resistance.
Study Details
Timeline
Interventions
Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.
Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.